- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT07662629
Addtional Effect of Hyperbaric Oxygen to Programmed Physical Activity on Musckoloskeletal Pain in Breast Cancer Elderly
June 17, 2026 updated by: Ali Mohamed Ali ismail, Cairo University
Addtion of Hyperbaric Oxygen to Programmed Physical Activity in Aromatse Inhibtors-linked Musckoloskeletal Pain in Breast Cancer Patients
patienst who survived from breast cancer are prescribed long administraion of aromatase inhbitors.. these inhibitors usually induce musckloskeletal pains.
Programmed phsyical activity are reommended to improve these pains but effects of HYperbaric oxygen on these pain was not investigated
Study Overview
Status
Recruiting
Conditions
Intervention / Treatment
Detailed Description
forty elder survivors from breast cancer with musckolskeletal pains resultes from aromatase inhibitor intake were assigned to two groups, group I and group II. the groups received phsyical activity program (aerobci training on traedmill and strengtheining protcol thrice weekly fro 2 month) but group II additinally received one-hour hyperbaric therapy session , five times weekly for 2 month.
Study Type
Interventional
Enrollment (Estimated)
40
Phase
- Not Applicable
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Contact
- Name: Ali MA Ismail, lecturer
- Phone Number: 01005154209
- Email: ali.mohamed@pt.cu.edu.eg
Study Contact Backup
- Name: ali moahmed, lecturer
- Phone Number: 01031321109
- Email: fatmaraed1994@gmail.com
Study Locations
-
-
Giza Governorate
-
Dokki, Giza Governorate, Egypt, 11432
- Recruiting
- Cairo University
-
Contact:
- ali AM Ismail, lecturer
- Phone Number: +201005154209
- Email: ali.mohamed@pt.cu.edu.eg
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
- Older Adult
Accepts Healthy Volunteers
No
Description
Inclusion Criteria:
- braest cancer survivors
- patients receiving aramatase inhibitor drugs
- patients with musckolskeletal pains
Exclusion Criteria:
- cardiac patients
- respiratory patients
- renal patients
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Single
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
|---|---|
|
Experimental: group number 1
Twenty elder survivors from breast cancer with musckolskeletal pains resultes from aromatase inhibitor intake received phsyical activity program (aerobci training on traedmill and strengtheining protcol thrice weekly fro 2 month) and additinally received one-hour hyperbaric therapy session , five times weekly for 2 month.
|
Twenty elder survivors from breast cancer with musckolskeletal pains resultes from aromatase inhibitor intake received phsyical activity program (aerobci training on traedmill and strengtheining protcol thrice weekly fro 2 month) and additinally received one-hour hyperbaric therapy session , five times weekly for 2 month.
|
|
Active Comparator: group number 2
Twenty elder survivors from breast cancer with musckolskeletal pains resultes from aromatase inhibitor intake received phsyical activity program (aerobci training on traedmill and strengtheining protcol thrice weekly fro 2 month)
|
Twenty elder survivors from breast cancer with musckolskeletal pains resultes from aromatase inhibitor intake received phsyical activity program (aerobci training on traedmill and strengtheining protcol thrice weekly for 2 month).
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
visual analogue scale
Time Frame: it will be measured after 2 months
|
it self asessmant of pain level
|
it will be measured after 2 months
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
worst pain
Time Frame: it will be measured after 2 months
|
it is a subscore of brief pain inventory
|
it will be measured after 2 months
|
|
pain severity
Time Frame: it will be measured after 2 months
|
it is a subscore of brief pain inventory
|
it will be measured after 2 months
|
|
pain related interference
Time Frame: it will be measured after 2 months
|
it is a subscore of brief pain inventory
|
it will be measured after 2 months
|
|
pain score
Time Frame: it will be measured after 2 months
|
it is a sub score of Western Ontario and McMaster Universities Osteoarthritis
|
it will be measured after 2 months
|
|
stifness score
Time Frame: it will be measured after 2 months
|
it is a sub score of Western Ontario and McMaster Universities Osteoarthritis
|
it will be measured after 2 months
|
|
fucntion score
Time Frame: it will be measured after 2 months
|
it is a sub score of Western Ontario and McMaster Universities Osteoarthritis
|
it will be measured after 2 months
|
|
total score of Western Ontario and McMaster Universities Osteoarthritis
Time Frame: it will be measured after 2 months
|
it is usualy used in patients with arthritic pains
|
it will be measured after 2 months
|
|
Disabilities of the Arm, Shoulder and Hand questionnaire
Time Frame: it will be measured after 2 months
|
the short form of it used in patients with arthritic pains
|
it will be measured after 2 months
|
|
fatigue severity scale
Time Frame: it will be measured after 2 months
|
it is used to assess fatigue
|
it will be measured after 2 months
|
|
Short Physical Performance Battery
Time Frame: it will be measured after 2 months
|
total score used to assess physical performance
|
it will be measured after 2 months
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Investigators
- Principal Investigator: Ali MA Ismail, lecturer, Cairo University
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start (Actual)
May 7, 2026
Primary Completion (Estimated)
September 1, 2026
Study Completion (Estimated)
September 1, 2026
Study Registration Dates
First Submitted
June 17, 2026
First Submitted That Met QC Criteria
June 17, 2026
First Posted (Actual)
June 23, 2026
Study Record Updates
Last Update Posted (Actual)
June 23, 2026
Last Update Submitted That Met QC Criteria
June 17, 2026
Last Verified
June 1, 2026
More Information
Terms related to this study
Additional Relevant MeSH Terms
- Neoplasms by Site
- Neoplasms
- Skin Diseases
- Breast Diseases
- Skin and Connective Tissue Diseases
- Breast Neoplasms
- Motor Activity
- Movement
- Musculoskeletal Physiological Phenomena
- Musculoskeletal and Neural Physiological Phenomena
- Therapeutics
- Respiratory Therapy
- Oxygen Inhalation Therapy
- Exercise
- Hyperbaric Oxygenation
Other Study ID Numbers
- IRB000-14233-82
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
No
Studies a U.S. FDA-regulated device product
No
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Breast Cancer
-
Northwestern UniversityEisai Inc.UnknownMale Breast Cancer | Stage II Breast Cancer | Stage IIIA Breast Cancer | Stage IIIB Breast Cancer | Triple-negative Breast Cancer | Stage IA Breast Cancer | Stage IB Breast Cancer | Stage IIIC Breast Cancer | Estrogen Receptor-negative Breast Cancer | Progesterone Receptor-negative Breast Cancer | HER2-negative...United States
-
University of Southern CaliforniaNational Cancer Institute (NCI)WithdrawnStage IV Breast Cancer | Stage II Breast Cancer | Stage IIIA Breast Cancer | Stage IIIB Breast Cancer | Triple-negative Breast Cancer | Stage IA Breast Cancer | Stage IB Breast Cancer | Stage IIIC Breast Cancer | Recurrent Breast Cancer
-
Oncoliq US IncRecruitingBreast Cancer Female | Breast Cancer Detection | Breast Cancer Early Stage Breast Cancer (Stage 1-3) | Breast Cancer With Low to Intermediate HER2 Expression | Breast Cancer - Female | Breast Cancer (Early Breast Cancer) | Breast Cancer - Ductal Carcinoma in Situ (DCIS) | Breast Cancer - Infiltrating...Argentina
-
University of California, IrvineNational Cancer Institute (NCI); National Institutes of Health (NIH)CompletedBreast Cancer | HER2-positive Breast Cancer | Stage II Breast Cancer | Stage IIIA Breast Cancer | Stage IIIB Breast Cancer | Stage IA Breast Cancer | Stage IB Breast Cancer | Stage IIIC Breast Cancer | Recurrent Breast Cancer | HER2-negative Breast CancerUnited States
-
University of WashingtonNational Cancer Institute (NCI)CompletedHER2-positive Breast Cancer | Stage IV Breast Cancer | Stage II Breast Cancer | Stage IIIA Breast Cancer | Stage IIIB Breast Cancer | Stage IA Breast Cancer | Stage IB Breast Cancer | Stage IIIC Breast Cancer | Estrogen Receptor-positive Breast CancerUnited States
-
Joseph Baar, MD, PhDCompletedBreast Cancer | Stage I Breast Cancer | Inflammatory Breast Cancer | Stage II Breast Cancer | Stage IIIA Breast Cancer | Stage IIIB Breast Cancer | Triple-negative Breast Cancer | Stage IIIC Breast CancerUnited States
-
Baylor Breast Care CenterRecruitingBreast Cancer | Breast Neoplasm | Triple Negative Breast Cancer | Triple Negative Breast Neoplasms | HER2-positive Breast Cancer | Breast Cancer Stage II | Breast Cancer Female | Breast Cancer Stage III | Estrogen Receptor-positive Breast Cancer | Hormone Receptor-positive Breast Cancer | Breast Cancer InvasiveUnited States
-
Case Comprehensive Cancer CenterNational Institute on Minority Health and Health Disparities (NIMHD)CompletedCancer Survivor | Stage IIIA Breast Cancer | Stage IIIB Breast Cancer | Stage IA Breast Cancer | Stage IB Breast Cancer | Stage IIA Breast Cancer | Stage IIB Breast Cancer | Stage IIIC Breast CancerUnited States
-
Innocrin PharmaceuticalCompletedBreast Cancer | Advanced Breast Cancer | Metastatic Breast Cancer | Triple Negative Breast Cancer | Male Breast Cancer | ER+ Breast Cancer | Cancer of the BreastUnited States
-
University of WashingtonNational Cancer Institute (NCI)CompletedInflammatory Breast Cancer | Male Breast Cancer | Stage II Breast Cancer | Stage IIIA Breast Cancer | Stage IIIB Breast Cancer | Stage IIIC Breast CancerUnited States
Clinical Trials on hyperbaric therapy and exercise
-
National Baromedical ServicesMayo Clinic; Dartmouth-Hitchcock Medical Center; Eastern Virginia Medical School and other collaboratorsCompletedCarcinoma, Squamous Cell | Cancer of the Head and NeckUnited States
-
Second Affiliated Hospital, School of Medicine,...Not yet recruiting
-
Jinan Central HospitalEnrolling by invitationBreast Cancer | Lung Metastasis | Hyperbaric Oxygen TherapyChina
-
Northwestern UniversityNational Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)RecruitingUlcerative ColitisUnited States
-
Omar AljitawiCompleted
-
University of British ColumbiaUnknown
-
University of VersaillesAssistance Publique - Hôpitaux de ParisTerminatedCarbon Monoxide PoisoningFrance
-
Bayside HealthNational Health and Medical Research Council, Australia; Monash UniversityCompletedTibial Fracture | Soft Tissue InjuryAustralia, Sweden, Chile, United States, Austria, India, Italy, Portugal, Czechia
-
Louisiana State University Health Sciences Center...U.S. Army Medical Research and Development CommandUnknownTraumatic Brain Injury | Post-Concussion SyndromeUnited States